IL-12 and Mutant P53 Peptide-Pulsed Dendritic Cells for the Specific Immunotherapy of Cancer

Journal of Immunotherapy

Volumn 19, Issue 6, 1996, Pages 414-418

  Gabrilovich, Dmitry I ^a,b   Cunningham, H Thomas ^a   Carbone, David P ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cancer; Dendritic cells; IL 12; p53

Indexed keywords

INTERLEUKIN 12; PEPTIDE DERIVATIVE; PROTEIN P53;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANIMALS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAVENOUS; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS, EXPERIMENTAL; PEPTIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030322318     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199611000-00005     Document Type: Article

References (15)

1. DiNapoli MR, Calderon CL, Lopez DM. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduced expression of the inducible nitric oxide synthase gene. J Exp Med 1996;183:1323-9.
2. Aoe T, Okamoto Y, Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 1995;181:1881-6.
3. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, von Fliedner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes: impaired response to mitogen-deriven stimulation despite T-cell receptor expression. Int J Cancer 1988; 42:659-66.
4. Ioannides C, Whiteside T. T cell recognition of human tumors: implication for molecular immunotherapy of cancer. Clin Immunol Immunopathol 1993;66:91-106.
5. Gabrilovich D, Ciernik F, Carbone DP. Dendritic cells in anti-tumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170:101-10.
6. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170:111-20.
7. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995;2:96-106.
8. Nastala CL, Edington HD, McKinney TG, et al. Recombinant interleukin-12 administration induces tumor regression in association with interferon-gamma and nitric oxide production. J Exp Med 1994;153:1697-706.
9. Noguchi Y, Richards EC, Chen Y-T, Old L. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995;92:2219-23.
10. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993;178:1223-30.
11. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-403.
12. + cytotoxic T-cells. Cancer Res 1993;53:3257-61.
13. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulated factor. J Exp Med 1992;176:1693-702.
14. Takahashi H, Cohen J, Hosmalin A, et al. An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988;85:3105-9.
15. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.